Tillmann Taube
Charité
29 Papers
446 Citations
Tillmann Taube is an academic researcher from Charité. The author has contributed to research in topics: Acute lymphocytic leukemia & Minimal residual disease. The author has an hindex of 17, co-authored 27 publications. Previous affiliations of Tillmann Taube include Humboldt University of Berlin & Humboldt State University.
Chat about Author
Papers
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Vivek Patel,Matthieu Mahévas,Soo Y. Lee,Roberto Stasi,Susanna Cunningham-Rundles,Bertrand Godeau,Julie Kanter,Ellis J. Neufeld,Tillmann Taube,Ugo Ramenghi,Shalini Shenoy,Mary J. Ward,Nino Mihatov,Vinay L. Patel,Philippe Bierling,Martin Lesser,Nichola Cooper,James B. Bussel +17 more
TL;DR: Only 21% to 26% of adults and children with chronic ITP treated with standard-dose rituximab maintained a treatment-free response for at least 5 years without major toxicity, which can inform clinical decision-making.
327
Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology.
Sven Wellmann,Tillmann Taube,Krisztina Paal,Hagen Graf v. Einsiedel,Wilhelm Geilen,Georg Seifert,Cornelia Eckert,Günter Henze,Karlheinz Seeger +8 more
TL;DR: Because of the ability for quantification of VEGF splice variants with high specificity, sensitivity, and reproducibility, this new LightCycler assay is superior to conventional semiquantitative competitive RT-PCR and immunological assays and may contribute to better understanding of V EGF-mediated angiogenesis.
133
Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
TL;DR: Twenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thromBocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody.
70
Deletion analysis of p16INKa and p15INKb in relapsed childhood acute lymphoblastic leukemia
Hagen Graf v. Einsiedel,Tillmann Taube,Reinhard Hartmann,Sven Wellmann,Georg Seifert,Günter Henze,Karl Seeger +6 more
TL;DR: In this paper, the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction was determined.
51
Relapse of TEL-AML1–Positive Acute Lymphoblastic Leukemia in Childhood: A Matched-Pair Analysis
Karl Seeger,Arend von Stackelberg,Tillmann Taube,Dirk Buchwald,Gabriele Körner,Meinolf Suttorp,Wolfgang Dörffel,Werner Tausch,Günter Henze +8 more
TL;DR: TEL-AML1 expression does not constitute an independent risk factor in relapsed childhood BCP-ALL after matching for relevant prognostic parameters, and undoubtedly characterizes genetically an ALL entity associated with established favorable progostic parameters.
43